– UK, York – OptiBiotix Health plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the appointment of Dr Gareth Barker as a Non-Executive Director of the Company.
Dr Gareth Barker is Vice President of Human Nutrition and Health for DSM Nutritional Products Europe AG, the global science-based nutrition company, within Europe, Africa and the Middle East. Prior to this he has worked in a number of roles for DSM including Global Head of Marketing for DSM’s Human Nutrition and Health Division and Sales Director in the Asia Pacific region, with responsibilities including launch strategies for Nutraceuticals. Gareth’s career has given him extensive experience and understanding of global markets within the health and nutrition sector.
Before joining DSM, Gareth worked for Hoffmann-la-Roche who he joined after working in consultancy advising clients in the Food & Pharmaceutical industries. Gareth has an MBA from Manchester Business School, a PhD from Oxford University, and is proficient in French, Spanish, and German.
DSM is a global science-based company active in health, nutrition and materials with a strong market focus. It has a marketing/sales presence in over 60 countries and is focused on translating market needs into successful products which bring health benefits to its customers. It is the world’s largest vitamin producer and hold leading positions in the ingredient markets for human and animal nutrition and health as well as personal care.
Stephen O’Hara, CEO of OptiBiotix, commented: “Gareth’s experience and understanding of global markets in human health and nutrition brings valuable market insight to OptiBiotix. Gareth’s expertise and guidance will help ensure the development of products which meet customer needs in global markets. This is consistent with our core strategy of developing products with a customer focus, supported by a strong scientific evidence base, to build a successful and sustainable business for our customers and shareholders. At OptiBiotix, we believe that better science equals better health and we strive to ensure this becomes a reality.”
About OptiBiotix
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome – the collective genome of the microbes in the body – to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
About DSM – Bright Science. Brighter Living.™
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM’s 24,500 employees deliver annual net sales of around €10 billion. The company is listed on NYSE Euronext.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
